Skip to main content
Health Podcast Library
Episode 824

Four Tubeless Pumps in 2027?! CGM studies in older people, new T1D insurance tool, ADA controversy continues, and more!

Episode Description

This week on Diabetes Connections In the News… two new tubeless pumps are cleared, a new way to check your diabetes insurance costs and find the right plan, study look at CGM use among older people with diabetes, the ADA Controversy Continues as Research Boycott Grows, and a look at some Diabetes Awareness Month campaigns..

Check out all of our events like Moms' Night Out and Club 1921 here. Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com

Transcript:

This week on Diabetes Connections In the News… a new tubeless pump is cleared, a new way to check your diabetes insurance costs and find the right plan, study look at CGM use among older people with diabetes, the ADA Controversy Continues as Research Boycott Grows, and a look at some Diabetes Awareness Month campaigns..

It's all coming up right after this.

(AD BREAK)

Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bring you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes.

We've got a lot to get to, so let's just dive in! Our top story this week:

XX

Big news – there are now FOUR tubeless insulin pumps FDA cleared. MiniMed Fit and tandem mobi tubeless cleared in the past week – add those to the Beta Bionics Mint and of course, the original, Omnipod.

Just yesterday, the FDA cleared the new MiniMed Fit system, which can be worn for up to seven days and holds 300 units of insulin. It has a reusable pump core and a Disposable cartridge – the cannula is built in, so no separate infusion set. Holds 300 units of insulin, with a built-in cannula and reliable adhesive for up to 7 day wear.

Reusable pump core — The brains of the pump, this rechargeable part attaches to the disposable cartridge. One charge lasts up to 7 days.The pump uses the same SmartGuard automated insulin delivery technology as MiniMed Flex, adjusting insulin and making corrections every five minutes.

The system is fully controlled by smartphone and will be available through pharmacies, with a phased U.S. rollout planned for 2027.

https://news.minimed.com/2026-11-16-FDA-Clears-MiniMed-Fit-TM-Worlds-First-and-Only-Tubeless-Insulin-Pump-with-Up-to-Seven-Day-Wear-and-Zero-Interruptions

XX

Just a few days ago, Tandem Diabetes Care received clearance clearance for a tubeless version of its Mobi insulin pump, with a wearable cartridge and infusion set designed to last up to seven days. Tandem plans a full U.S. launch in the first half of 2027, with distribution exclusively through pharmacies. This gives people with type 1 another potential option for automated insulin delivery without traditional pump tubing.

https://www.drugdeliverybusiness.com/tandems-mobi-pump-wins-fda-clearance-for-7-day-tubeless-wearable-set/

In other Tandem news, the company has issued a recall-related correction affecting more than 80,000 Mobi insulin pumps because of a problem that can trigger false occlusion alarms and interrupt insulin delivery. As of late October, Tandem had received reports of 230 adverse events requiring medical attention or hospitalization, although no deaths had been reported. The issue involves friction inside the pump's motor mechanism, which can cause the device to mistakenly detect a blockage. Tandem says customers can continue using their pumps but should respond promptly to alarms, keep a backup insulin delivery method available, and contact customer support if alarms repeatedly interrupt therapy. The company is investigating the problem and working to prevent it in future devices.

https://www.medtechdive.com/news/tandem-recalls-mobi-insulin-pump-reports-230-adverse-events/874386/

XX

Just in time for open enrollment, a new free tool aims to make choosing health insurance a little less overwhelming for people with diabetes. The GlucoSense Insurance Navigator compares 2027 Marketplace plans based on what you'll actually spend over the course of a year, not just your monthly premium. It factors in deductibles, insulin, CGMs, pump supplies, doctor visits, and even manufacturer savings cards to estimate your total annual costs. The tool's developers say early users have identified plans that could save them thousands of dollars a year. It's available through the GlucoSense app, although you'll still want to confirm coverage and costs directly with your insurance company before enrolling. Hat Tip to Justin from Diabetech as my source here..

https://www.diabetech.info/p/glucosense-launches-tool-to-help-people-with-diabetes-choose-insurance

XX

For the first time, the World Health Organization has issued guidelines specifically for diagnosing and managing type 1 diabetes in adults. Released on World Diabetes Day, the recommendations focus on making insulin, blood glucose monitoring, and quality care accessible worldwide, including in countries with limited healthcare resources. The WHO estimates that 9.5 million people worldwide were living with type 1 diabetes in 2025, with another half-million diagnosed that year. The guidelines recommend multiple daily insulin injections, regular glucose monitoring, and the use of CGMs when available. The larger goal is to ensure everyone with type 1 has access to affordable insulin and glucose monitoring by 2030.

https://www.who.int/news/item/14-11-2026-who-issues-first-guidelines-on-type-1-diabetes-for-adults

XX

XX

The FDA is requiring new safety warnings on all GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and Zepbound, because of a possible connection to a rare eye condition that can cause sudden vision loss. The condition, called NAION, occurs when blood flow to the optic nerve is reduced and can sometimes cause permanent damage. An analysis of clinical trials found about 6.4 cases per 100,000 patient-years among GLP-1 users, compared with 3.8 among those receiving other treatments or placebos. The FDA says the risk appears very small and researchers have not established that the medications directly cause the condition. Diabetes itself is also a risk factor, making the connection more difficult to untangle. We have an episode coming up next week where we'll talk a bit more about his.

https://www.cnbc.com/2026/11/10/fda-warning-vision-loss-glp1-wegovy-zepbound.html

A new study of more than 8,400 adults with type 1 diabetes in the Veterans Health Administration found that people who started using CGMs had a lower risk of death over the following four years. The estimated reduction in mortality risk was about 16 percent at four years, with potentially greater benefits for adults over 65 and those not using insulin pumps. Researchers emphasize that this was an observational study, so it doesn't prove CGMs directly caused the improvement. Still, the findings add another compelling argument for expanding access to diabetes technology.

https://www.emjreviews.com/en-us/amj/diabetes/abstract/continuous-glucose-monitoring-initiation-is-associated-with-reduced-mortality-in-older-patients-with-type-1-diabetes-a-target-trial-emulation-study-using-national-healthcare-data-j04126/

XX

XX

Researchers are getting closer to understanding a long-standing mystery in type 1 diabetes: why children whose mothers have type 1 are about half as likely to develop the condition as children whose fathers have it. A University of Colorado study followed nearly 7,000 children at increased genetic risk and found that inherited genes don't explain the difference. The protective effect appears to happen early in life, particularly before age six, when the immune system may begin attacking insulin-producing cells. Researchers also found no evidence that pregnancy loss explains the difference, as some had previously suggested. The next step is figuring out what biological process might be providing that protection and whether it could eventually help prevent type 1 diabetes.

https://medicalxpress.com/news/2026-11-genetic-maternal-effect-diabetes.html

XX

Researchers in Israel are reporting promising early results from an experimental treatment for LADA, sometimes called type 1.5 diabetes. Scientists at Bar-Ilan University combined three drugs — GABA, sitagliptin, and omeprazole — and found that about 30 percent of treated mice returned to normal blood sugar levels without insulin, even after treatment ended. The researchers also identified blood markers that could predict which mice would respond, potentially opening the door to more personalized treatments. LADA is a form of autoimmune diabetes that typically develops more slowly in adults. This research is still in mice, not humans, but it offers an interesting new direction for treating autoimmune diabetes.

https://www.timesofisrael.com/israeli-scientists-use-common-drugs-to-cure-30-of-mice-with-type-1-5-diabetes/

XX

A fully automated artificial pancreas that delivers both insulin and glucagon is showing mixed results in a new year-long study involving more than 240 adults with type 1 diabetes. Unlike current hybrid closed-loop pumps, this system doesn't require users to count carbs, announce meals, or make adjustments for exercise. Researchers found it improved time in range by nearly two hours a day compared with multiple daily injections, but offered no significant advantage over existing automated insulin delivery systems. The biggest challenge? Half of the people assigned to the new device stopped using it before the study ended, largely because of the hassle of wearing two infusion sets, two sensors, and dealing with frequent alarms. Researchers say the technology is promising, but it needs to become much easier to use before it can compete with today's insulin pumps.

XX

Here's an unexpected connection between air quality and glucose levels. Researchers at NYU Langone Health found that people with prediabetes who slept with HEPA air filters in their bedrooms experienced smaller blood sugar swings and lower glucose spikes after breakfast. The month-long study included more than 150 adults, with participants wearing CGMs to track changes in their glucose levels. Those using working air filters saw nearly an eight percent reduction in daily glucose fluctuations, along with a 13 percent reduction in peak blood sugar after breakfast. The researchers caution that these results may not apply to people who already have diabetes, but the findings suggest indoor air quality could play a role in metabolic health.

https://nyulangone.org/news/cleaner-bedroom-air-may-help-manage-blood-sugar-prediabetes

XX

The controversy surrounding the American Diabetes Association is far from over, with a growing boycott now threatening the organization's scientific journals and conferences. Nearly 1,200 researchers and medical experts have pledged to stop working with ADA publications or presenting at its meetings following the removal of five researchers from the ADA's scientific conference in New Orleans earlier this year. The dispute has expanded beyond the original incident into broader concerns about censorship, academic freedom, and leadership at the organization. The ADA has defended its security decisions but acknowledged that three of the five researchers likely should not have been removed. The New York Times reports that journal submissions have slowed, editors have stopped working, and some international researchers are reconsidering attending future ADA conferences.

https://www.nytimes.com/2026/11/09/science/american-diabetes-association-turmoil.html

XX

Some diabetes awareness month news.. and projects

Nick Jonas is sharing a very personal look at life with type 1 diabetes, including the parts he doesn't always appreciate. In an open letter released as part of Dexcom's National Diabetes Awareness Month campaign, the singer reflects on 21 years of managing the condition and the hundreds of small decisions that come with it. He admits that while diabetes has taught him important lessons, there are still days when he resents it and wonders what life would be like without it. But he also credits the diabetes community with helping him find a sense of belonging he struggled to find growing up. Jonas says he continues speaking openly about type 1 so newly diagnosed kids can see someone living their dreams while managing diabetes.

https://people.com/nick-jonas-shares-what-he-resents-about-having-diabetes-12238940

XX

T1D to 100 launches a new project: Living Legends features people with who've lived with T1D for more than 75 years. T1D to 100 is a group launched last year by the incomparable Joanne Milo. Julian Rubin, featured in our first Living Legend interview was diagnosed in May, 1945 and is 91 years old

https://www.facebook.com/groups/t1dto100

XX

There's a new superhero in the Marvel universe, and he wears an insulin pump! Insulet has teamed up with Marvel Comics again to introduce Gluconaut, a teenage superhero with type 1 diabetes who uses Omnipod. The new comic, Gluconaut: Strength of Stars, follows a high school student named Podrick as he struggles with feeling different because of his diabetes technology before discovering his own confidence and strength. The story was written by Pallie Paul Allor, who lives with diabetes, and is designed to help young people feel represented rather than defined by their diagnosis. Insulet says the project responds to feedback from the diabetes community asking for more authentic representation in popular culture.

https://www.fiercepharma.com/marketing/insulet-marvel-comics-smash-diabetes-stigma-new-omnipod-powered-superhero

Proudly Supported by

BetterHelpForvis MazarsAAOSCalendarPAmowPod

Patrons of Health Podcast Library

Achieving Health
AAOS Career Podcast
OrthoInfo
AAOS Now Podcast
Who the Health Cares? with Prof Michael Sparer
Stronger After Stroke
Aging Like a Pro

Supporting Shows

Speak Up For Your Health
HITea With Grace
Beyond Clinical Walls
Impulse | Meeting Healthcare Pioneers
Thriving with Addiction with Dr. Jonathan Avery
Cuts and Consults
Beyond The Paper Gown Podcast
Faces of Digital Health
Healthcare for Humans
Nurse Rosa's INsights
Coaching Healthcare Leaders
This Just In Radio Show
Coffee Break: Breaking the Cycle of Bullying in Healthcare, One Cup at a Time
HIT Like a Girl Pod: Empowering Women in Health IT
On the Pulse Podcast
Hopeful Hints

We use cookies to run this site. Analytics cookies, which show us how it's used, stay off unless you accept them. Change your mind any time with the cookie button at the bottom right. How we use cookies